» Articles » PMID: 19366234

Extracellularly Activated Nanocarriers: a New Paradigm of Tumor Targeted Drug Delivery

Overview
Journal Mol Pharm
Specialty Pharmacology
Date 2009 Apr 16
PMID 19366234
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

One of the main goals of nanomedicine is to develop a nanocarrier that can selectively deliver anticancer drugs to the targeted tumors. Extensive efforts have resulted in several tumor-targeted nanocarriers, some of which are approved for clinical use. Most nanocarriers achieve tumor-selective accumulation through the enhanced permeability and retention effect. Targeting molecules such as antibodies, peptides, ligands, or nucleic acids attached to the nanocarriers further enhance their recognition and internalization by the target tissues. While both the stealth and targeting features are important for effective and selective drug delivery to the tumors, achieving both features simultaneously is often found to be difficult. Some of the recent targeting strategies have the potential to overcome this challenge. These strategies utilize the unique extracellular environment of tumors to change the long-circulating nanocarriers to release the drug or interact with cells in a tumor-specific manner. This review discusses the new targeting strategies with recent examples, which utilize the environmental stimuli to activate the nanocarriers. Traditional strategies for tumor-targeted nanocarriers are briefly discussed with an emphasis on their achievements and challenges.

Citing Articles

Self-assembly of multi-arm star PEG containing TXA9 into nanoparticle for the efficient chemotherapy of NSCLC.

Wang Q, Liu Z, Yao J, Xie H, Liu Z, Zhai J Drug Deliv Transl Res. 2025; .

PMID: 39833467 DOI: 10.1007/s13346-025-01793-0.


Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine.

Gulwani D, Upadhyay P, Goel R, Sarangthem V, Singh T Discov Oncol. 2024; 15(1):789.

PMID: 39692930 PMC: 11656002. DOI: 10.1007/s12672-024-01677-8.


Nanocarriers for Cannabinoid Delivery: Enhancing Therapeutic Potential.

Singh V, Vihal S, Rana R, Rathore C Recent Adv Drug Deliv Formul. 2024; 18(4):247-261.

PMID: 39356097 DOI: 10.2174/0126673878300347240718100814.


Green Nanotechnology Through Papain Nanoparticles: Preclinical in vitro and in vivo Evaluation of Imaging Triple-Negative Breast Tumors.

Ferreira A, Marques F, Real C, Thipe V, Freitas L, Lima C Nanotechnol Sci Appl. 2024; 17:211-226.

PMID: 39346128 PMC: 11439364. DOI: 10.2147/NSA.S474194.


Polydopamine-Based Targeted Nanosystem for Chemo/Photothermal Therapy of Retinoblastoma in a Mouse Orthotopic Model.

Jin B, Lu K, Gao W, Liu Y, Wang M, Zhang X Int J Nanomedicine. 2024; 19:7799-7816.

PMID: 39099794 PMC: 11297587. DOI: 10.2147/IJN.S467949.


References
1.
Chau Y, Padera R, Dang N, Langer R . Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models. Int J Cancer. 2005; 118(6):1519-26. DOI: 10.1002/ijc.21495. View

2.
Ko J, Park K, Kim Y, Kim M, Han J, Kim K . Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy. J Control Release. 2007; 123(2):109-15. DOI: 10.1016/j.jconrel.2007.07.012. View

3.
Kaasgaard T, Mouritsen O, Jorgensen K . Screening effect of PEG on avidin binding to liposome surface receptors. Int J Pharm. 2001; 214(1-2):63-5. DOI: 10.1016/s0378-5173(00)00633-5. View

4.
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

5.
Gabizon A, Shmeeda H, Barenholz Y . Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003; 42(5):419-36. DOI: 10.2165/00003088-200342050-00002. View